NICE recommends Bristol-Myers Squibb ’s nivolumab for NSCLC patients on NHS

The UK National Institute for Health and Care Excellence (NICE) has recommended Bristol-Myers Squibb ’s immunotherapy drug Opdivo (nivolumab) for NHS use through the Cancer Drugs Fund (CDF) for the treatment of advanced non-small-cell lung cancer (NSC…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news